FDA Pulls Back on Stricter Rules for Tanning Beds and Sunlamps
Published Date: 3/16/2026
Proposed Rule
Summary
The FDA has decided to stop moving forward with a 2015 plan that would have put stricter rules on selling and using sunlamp products like tanning beds. This means businesses and users won’t face new restrictions or extra costs from this rule. The withdrawal is official as of March 16, 2026, so things stay as they are for now.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Existing 2014 Sunlamp Rules Still Apply
Sunlamp products were reclassified to class II in a June 2, 2014 order that became effective September 2, 2014, making them subject to 510(k) premarket notification and special controls. Those special controls include performance testing, labeling requirements, and a warning that sunlamp products should not be used on persons under age 18.
Proposed Sunlamp Restrictions Withdrawn
The FDA withdrew its December 22, 2015 proposed rule on restricting sale, distribution, and use of sunlamp products. As of March 16, 2026, businesses and users will not face the new restrictions or extra costs that would have come from that proposed rule, so current practices remain in place for now.
Performance Standard Amendments Unaffected
FDA said its proposed amendments to the sunlamp products and UV lamps performance standard at 21 CFR 1040.20 are not affected by this withdrawal. That means the separate proposed technical and labeling updates at 21 CFR 1040.20 remain a separate action.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-05097, Amendment of Class D and Class E Airspace and Revoke Class E Airspace; Fort Knox, KY
The FAA is updating the airspace rules around Fort Knox, KY, because an old navigation beacon was turned off. This means changing some flight zones and removing others to keep things safe and clear for pilots. If you fly or work near Fort Knox, these changes could affect you starting soon, and the FAA wants your feedback by April 30, 2026.
Next: 2026-05105, Prediction Markets
The Commodity Futures Trading Commission (CFTC) is asking for your thoughts on prediction markets—places where people bet on future events. They want to know what rules should apply, which bets might be off-limits, and how these markets impact everyone. If you have ideas, send them by April 30, 2026, because this could lead to new rules that affect traders and the public.